<DOC>
	<DOC>NCT02627274</DOC>
	<brief_summary>This open-label, multicenter, dose-escalation study will evaluate the safety, pharmacokinetics and therapeutic activity of RO6874281 in participants with advanced and/or metastatic solid tumors. Participants will be treated until disease progression or unacceptable toxicity occurs, for up to a maximum of 24 months.</brief_summary>
	<brief_title>A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Age greater than or equal to (&gt;=) 18 years Confirmed advanced and/or metastatic solid tumor, with at least one tumor lesion of location accessible to biopsy per clinical judgment of the treating physician, and confirmed progression at baseline; who have progressed on a cancer therapy or for whom no effective standard therapy exists Radiologically measurable and clinically evaluable disease Life expectancy of &gt;=12 weeks Eastern Cooperative Oncology Group (ECOG) Performance Status 0 1 Adequate cardiovascular, hematological, liver and renal function All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to Grade less than or equal to (&lt;=) 1, except alopecia (any grade) and Grade 2 peripheral neuropathy Negative serum pregnancy test within 7 days prior to study treatment in premenopausal women and women less than (&lt;) 12 months after menopause For women who are not postmenopausal and have not undergone surgical sterilization: agreement to remain abstinent or use two adequate non hormonal methods of contraception, including at least one method with a failure rate of &lt;1 percent (%) per year, during the treatment period and for at least 4 months after the last dose of study drug For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm during the treatment period and for at least for at least 2 months after the last dose of study drug Participants with Gilbert's syndrome will be eligible for the study History or clinical evidence of Central Nervous System (CNS) primary tumors or metastases including leptomeningeal metastases, unless they have been previously treated, are asymptomatic, and have had no requirement for steroids or enzyme inducing anticonvulsants in the last 14 days prior to screening Participants with an active second malignancy Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including diabetes mellitus, history of relevant pulmonary disorders, and known autoimmune diseases or other disease with ongoing fibrosis Significant cardiovascular/cerebrovascular disease within 6 months prior to Day 1 of study drug administration Active or uncontrolled infections Known human immunodeficiency virus (HIV) or known active hepatitis B virus or hepatitis C virus infection History of chronic liver disease or evidence of hepatic cirrhosis Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that give reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug Major surgery or significant traumatic injury &lt;28 days prior to the first RO6874281 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment Dementia or altered mental status that would prohibit informed consent Pregnant or breastfeeding women Known hypersensitivity to any of the components of RO6874281 Concurrent therapy with any other investigational drug Immunomodulating agents &lt;28 days prior to first dose of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>